Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
BMC Infect Dis. 2023 May 11;23(1):320. doi: 10.1186/s12879-023-08289-7.
Numerous vaccination research experiments have been conducted on non-primate hosts to prevent or control HTLV-1 infection. Therefore, reviewing recent advancements for status assessment and strategic planning of future preventative actions to reduce HTLV-1 infection and its consequences would be essential.
MEDLINE, Scopus, Web of Science, and Clinicaltrials.gov were searched from each database's inception through March 27, 2022. All original articles focusing on developing an HTLV-1 vaccine candidate were included.
A total of 47 studies were included. They used a variety of approaches to develop the HTLV-1 vaccine, including DNA-based, dendritic-cell-based, peptide/protein-based, and recombinant vaccinia virus approaches. The majority of the research that was included utilized Tax, Glycoprotein (GP), GAG, POL, REX, and HBZ as their main peptides in order to develop the vaccine. The immunization used in dendritic cell-based investigations, which were more recently published, was accomplished by an activated CD-8 T-cell response. Although there hasn't been much attention lately on this form of the vaccine, the initial attempts to develop an HTLV-1 immunization depended on recombinant vaccinia virus, and the majority of results seem positive and effective for this type of vaccine. Few studies were conducted on humans. Most of the studies were experimental studies using animal models. Adenovirus, Cytomegalovirus (CMV), vaccinia, baculovirus, hepatitis B, measles, and pox were the most commonly used vectors.
This systematic review reported recent progression in the development of HTLV-1 vaccines to identify candidates with the most promising preventive and therapeutic effects.
为了预防或控制 HTLV-1 感染，人们在非灵长类宿主身上进行了大量疫苗研究实验。因此，评估 HTLV-1 感染的现状，并为未来的预防行动制定战略计划，以减少 HTLV-1 感染及其后果，这是非常必要的。
从每个数据库的创建到 2022 年 3 月 27 日，我们在 MEDLINE、Scopus、Web of Science 和 Clinicaltrials.gov 上进行了检索。所有关注开发 HTLV-1 疫苗候选物的原始文章都被包括在内。
共有 47 项研究被纳入。他们采用了多种方法来开发 HTLV-1 疫苗，包括基于 DNA、树突状细胞、肽/蛋白和重组痘苗病毒的方法。纳入的大多数研究都使用 Tax、Glycoprotein (GP)、GAG、POL、REX 和 HBZ 作为其主要肽来开发疫苗。最近发表的基于树突状细胞的研究中使用的免疫接种是通过激活 CD-8 T 细胞反应来实现的。尽管最近人们对这种疫苗形式关注较少，但开发 HTLV-1 免疫接种的最初尝试依赖于重组痘苗病毒，并且大多数结果似乎对这种类型的疫苗有效。对人类进行的研究很少。大多数研究都是使用动物模型的实验研究。腺病毒、巨细胞病毒 (CMV)、痘苗病毒、杆状病毒、乙型肝炎、麻疹和痘病毒是最常用的载体。
本系统评价报告了 HTLV-1 疫苗开发的最新进展，以确定具有最有前途的预防和治疗效果的候选疫苗。
